TxCell Share Price

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time Euronext Paris 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 11/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+1.06%+0.05%+61.46%+112.00% 54.54B
-1.22%+5.01%+43.38%+36.69% 43.86B
-1.43%+3.47%-15.83%-20.48% 22.63B
-1.99%-3.55%-5.97%+377.60% 20.7B
-0.53%+0.54%+16.19%-36.06% 15.84B
+2.88%-0.44%+11.10%-39.40% 14.83B
-1.70%-1.68%+24.79%+172.92% 13.1B
-5.17%+0.50%+21.80% - 12.66B
+0.29%+5.10%+75.82%+105.33% 11.56B
Average -0.79%+1.21%+25.86%+88.57% 23.3B
Weighted average by Cap. -0.58%+0.74%+31.81%+88.29%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!